Publications by authors named "Nikolay Evgeniev"
Article Synopsis
- XAV-19 is a targeted swine polyclonal antibody for SARS-CoV-2 that was tested for safety and effectiveness in patients with mild to moderate COVID-19 in a clinical trial.
- The trial was a phase II/III, double-blind, placebo-controlled study involving 279 patients where the primary focus was on whether XAV-19 could prevent disease worsening within eight days of treatment.
- Results indicated that while there were no significant differences in the primary endpoint, XAV-19 accelerated recovery times, particularly for patients with lower severity scores, and demonstrated effective neutralization against various COVID-19 variants.
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron.
Open Forum Infect Dis
June 2023
Article Synopsis
- Safe and effective treatments are crucial for preventing severe COVID-19 outcomes, which is the focus of the STAMP trial on adintrevimab, an extended half-life monoclonal antibody for high-risk patients with mild to moderate symptoms.
- In the study, unvaccinated participants aged 12 and older were given either adintrevimab or placebo, but enrollment was paused when the Omicron variant emerged, as the treatment showed reduced effectiveness against it.
- Results demonstrated that 4.7% of the adintrevimab group faced hospitalization or death within 29 days, compared to 13.8% in the placebo group, indicating a significant 66% reduction in risk, and no serious adverse events